ponatinib (Iclusig) -

ponatinib (Iclusig)
Information type: Drug best practice guidance
Source: Scottish Medicines Consortium
Specialities: Cancers
Summary
The Scottish Medicines Consortium has accepted ponatinib (Iclusig®) for use within NHS Scotland for the treatment of adults with chronic phase, accelerated phase, or blast phase CML, or Ph+ALL, who meet certain criteria regarding previous therapies and/ or T315I mutation status.
UKMi comment
Ponatinib is listed on the National Cancer Drugs Fund List (last updated March 2015; version 4.0) for the treatment of CML with T315I mutation and Ph+ ALL with T315I mutation, provided the listed criteria are met (please see the link below for further details).
Related links: National Cancer Drugs Fund List